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ABSTRACT The class II transactivator (CIITA) is a
master transcription regulator of gene products involved in
the exogenous antigen presentation pathway, including major
histocompatibility complex (MHC) class II, invariant chain,
and DM. An extensive analysis of the putative functional
domains of CIITA is undertaken here to explore the action of
CIITA. Antibodies to CIITA protein were produced to verify
that these mutant proteins are expressed. Both acidic and
prolineyserineythreonine-rich domains are essential for class
II MHC promoter activation. In addition, three guanine
nucleotide-binding motifs are essential for CIITA activity. Of
these mutants, two exhibited strong transdominant-negative
functions. These two mutants provide a plausible approach to
manipulate MHC class II expression and immune responses.
Major histocompatibility complex (MHC) gene products DR,
DP, andDQ play a critical role in the presentation of processed
exogenous antigen to T cells (1–3). MHC class II molecules are
constitutively expressed at high levels in B lymphocytes and
dendritic cells and are induced in certain cell types such as
macrophages, endothelial cells, astrocytes, and microglia upon
treatment with interferon-g (IFN-g). The appropriate consti-
tutive and inducible expression of MHC class II molecules is
essential for normal immune response, whereas aberrantly
high and low expression have been correlated with various
autoimmune diseases (4, 5) and a type of severe combined
immunodeficiency disease, the bare lymphocyte syndrome
(BLS), respectively (6, 7). Patients with BLS lack MHC class
II antigen expression on both constitutive and IFN-g-inducible
cells (8, 9). The lack of MHC class II antigen expression on
cells from group A of type II BLS patients is primarily due to
a defect in the transcription factor, class II transactivator
(CIITA), initially identified as AIR-1 (10, 11).
The primary regulation of constitutive and IFN-g-induced
MHC class II genes is at the transcriptional level (9, 12, 13).
The MHC class II, invariant chain, and DMAyDMB genes
contain three highly conserved DNA cis-acting elements: the
W, X, and Y boxes (14), also known collectively as the class II
box. These three elements exhibit conservation in sequence, as
well as spacing constraint and regimented stereospecific align-
ment (15, 16).
The transcription factors that directly bind to the MHC class
II promoter elements are well studied (9, 12, 17), but expres-
sion of these proteins is generally ubiquitous and does not
parallel MHC class II gene expression. In contrast, expression
of CIITA closely parallels that ofMHC class II gene expression
(11). CIITA was cloned by its ability to complement RJ2.2.5,
an in vitro-generated MHC class II negative cell derived from
Raji (11, 18). Several groups, including our own, have shown
that CIITA is induced by IFN-g and that transfection of CIITA
alone into cells is sufficient to activate MHC class II (19–21),
invariant chain (19, 22), and HLA-DM genes (22).
A major issue in the field concerns the mode of action of
CIITA. Although CIITA is a strong transactivator, it does not
bind MHC class II promoter elements, nor does it appear to
interact with transcription factors that bind these elements. In
this report, we have undertaken an extensive domain analysis
to delineate functional domains of CIITA. The results show
that the proline-, serine-, and threonine-rich domains are
critical for function. In addition, a GTP-binding domain
consisting of phosphate-, Mg21-, and guanine-binding motifs is
crucial for CIITA function, strongly implicating a role for GTP
binding. Two of the mutants are highly efficient transdomi-
nant-negative molecules that nearly abolished the normal
function of CIITA. The biological implications of these ob-
servations are discussed.
MATERIALS AND METHODS
Cell Cultures and Transient Transfection. 2fTGH, G3A,
Raji, Namalwa, and RJ2.2.5 cells were cultured as previously
described (18, 19, 23). COS-7, a T antigen-transformed mon-
key kidney cell line, was maintained in DMEM-H medium
containing 10% fetal calf serum (GIBCOyBRL). 2fTGH,
G3A, and RJ2.2.5 cells were transfected as described previ-
ously (19, 24).
DNA Constructs. The mammalian expression vector,
pcDNA3.FLAG.CIITA8 (FLAG.CIITA8), contains the
FLAG epitope (DYKDDDDK) upstream of the first methi-
onine of CIITA8. All mutant constructs were generated by a
published method (25) from the parental plasmid, FLAG.CI-
ITA8, with a selection primer, 59-AAATGCTTCAAT-
gcTAGcgAAAAAGGAAG-39, which mutated a SspI to NheI
restriction site, and a mutagenic primer. All mutants were
initially identified by the presence of an NheI site and later
confirmed by sequencing.
Construction Of ProlineySerineyThreonine Deletion Mu-
tants. CIITA(D132–301) was constructed by creating ClaI
restriction sites at nucleotides 511 (amino acids 132–133) and




mutagenized construct was digested with ClaI to release the
prolineyserineythreonine-containing fragment, and the re-
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maining sequence was in the plasmid religated. CIITA(D132–




TTTC-724-39, and it contained a clean deletion of the proliney
serine-rich domain. CIITA(D209–301) has deleted threonine-
rich domain from amino acid residues of 209–301. This mutant




Construction Of Nucleotide-Binding Motif Mutants. CI-
ITA-GTP1(DGK) and CIITA-GTP1(K3E) were mutated in
the phosphate-binding motif. CIITA-GTP1(DGK) has a de-
letion of two amino acid residues, 420 and 421, by a ‘‘loop out’’
mutagenic primer: 59-1395-CTCTTGCCCTGACCAGCCAC-
AGCAATCACTCGTG-1353-39. CIITA-GTP1(K3 E) has a
point mutation at residue 427 from lysine to glutamic acid. The
mutagenic primer used to generate this mutant was 59-1408-
CCCAGCCCAATAGCTCTcGCCCTGACCAGCTTTGCC-
1373-39. CIITA-GTP2(DDAYG) and CIITA-GTP3(DSKAD)
have deletions in the Mg21- and guanine-binding motifs,
respectively. CIITA-GTP2(DDAYG) was created by a loop
out primer: 59-1522-GAGCAGATCCTGCAGCCCCG-
GACGGTTCAAG-1480-39. Mutagenic primer used to con-
struct GTP3(DSKAD) was 59-1813-CAGCTCAAAT-
AGGGCCAGGCTCTGGACCAG-1777-39.
Generation of Stable Transfectants Expressing Cell Surface
MHC Class II Antigen with FLAG.CIITA8 Expression Vector.
Ten micrograms of FLAG.CIITA8 plasmid was transfected
into G3A cell. The stable transfectants expressing cell surface
MHC class II antigens were selected by the immunomagnetic
selection, according to manufacturer is protocol (Dynal, Oslo).
The cells underwent immunoselection three times for the next
4 weeks. Cells expressing MHC class II antigens were con-
firmed by fluorescence-activated cell sorting analysis (19).
Anti-CIITA (a-CIITA) Antibody Production. Anti-human
CIITA antibody was raised against a peptide, 726GEIKD-
KELPQYLALTPR742, crosslinked to KLH (keyhole limpet
hemocyanin; Pierce). The antiserum was tested after numer-
ous injections of the rabbit with the antigen.
Western Blot. Raji, Namalwa, and RJ2.2.5 nuclear extracts
were prepared according to Dignam et al. (26). Whole cell
extract was prepared as described (27). The samples were
analyzed by immunoblotting with a-FLAG (10 mgyml; IBI–
Kodak) or a-CIITA (1.5 mgyml) antibodies using standard
techniques (27). Immunoblots were detected by enhanced
chemical luminescence (ECL; Amersham).
RESULTS
Generation and Characterization of CIITA Antibody. Anal-
ysis of the primary amino acid sequence of CIITA did not show
any homology to known conserved DNA-binding motif of
transcription factors, and in vitro-translated CIITA apparently
does not interact with DNA (11). In a separate study, our
laboratory shows that CIITA is not detected in a complex that
consists of proteins binding to theW, X, and Y elements (K. L.
Wright, K.-C.C., and J.P.-Y.T., unpublished work). A struc-
ture–function analysis is undertaken here to identify the
crucial domains of CIITA in an effort to understand its mode
of action. To accurately assess the effects of mutagenesis on
CIITA, it is essential to verify that mutant proteins are
expressed to a similar level as wild-type controls. Several
reagents were generated to assess this issue. First, a FLAG
epitope-tagged CIITA was produced. FLAG was chosen be-
cause this epitope is small (8 aa) and is not likely to disrupt the
native conformation of CIITA.
FLAG epitope-tagged CIITA, FLAG.CIITA8, functioned
equally as well as wild-type CIITA to transactivate MHC class
II promoter, as assessed by both the chloramphenicol acetyl-
transferase (CAT) reporter gene (Fig. 1A) and surface MHC
class II antigen expression (Fig. 1B). The former was assessed
by transfecting either FLAG-tagged or unmodified CIITA-
expression vector together with DRA300CAT into a CIITA-
defective cell line, G3A. pDRA300CAT (28) contains 267 bp
of the DRA promoter linked to CAT reporter gene (28, 29).
FLAG-tagged CIITA functioned properly in this transactiva-
tion assay (Fig. 1A). The latter was performed using similarly
transfected G3A cells, and the results were analyzed by flow
cytometry. The wild-type parent, 2fTGH, was responsive to
IFN-g (Fig. 1 Ba and Bb) as expected, while the G3A cell line
(Fig. 1 Bc and Bd) was not. Transfection of FLAG-tagged
CIITA into G3A cells resulted in high levels of surface MHC
class II (Fig. 1 Be and Bf ).
FIG. 1. The FLAG foreign epitope did not alter CIITA activity. (A)
FLAG.CIITA8 activated the DRA promoter in G3A cells. G3A cells
were cotransfected with the pDRA300CAT construct and an empty
vector (lane 1), CIITA expression vector (lane 2), or FLAG.CIITA8
(lanes 3 and 4). The cells were harvested and analyzed for CAT activity
48 h after transfection. (B) FLAG.CIITA8 induces HLA-DRA ex-
pression on the MHC class II-negative G3A mutant cells. 2fTGH cells
(Ba and Bb), G3A (Bc and Bd), and G3A (Be and Bf) stably integrated
with FLAG.CIITA8 were not treated (Left) or treated (Right) with 500
unitsyml of IFN-g for 72 h. The cells were harvested and analyzed for
surface HLA-DR antigen expression by a FACScan (Becton Dickin-
son).
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The expression of recombinant CIITA protein in 2fTGH
and COS-7 cells transfected with FLAG.CIITA8 was examined
by Western blot analysis. Recombinant CIITA migrated at an
apparent molecular weight of 145 kDa in SDSyPAGE and
specifically was recognized by the a-FLAG antibody (Fig. 2A,
lanes 1–4).
A second serologic reagent, a-CIITA antibody, was gener-
ated against a CIITA peptide (seeMaterials and Methods). The
specificity of this antibody was tested using extracts from
2fTGH and RJ2.2.5 cells transfected with pcDNA3 or FLAG.
CIITA8. Whole cell extracts were made after transfection and
analyzed by Western blot with a-FLAG and a-CIITA anti-
bodies. Both antibodies recognized an '145-kDa molecule in
FLAG.CIITA8 transfected 2fTGH and RJ2.2.5 cells (Fig. 2B
Top and Middle, lanes 2–4). This band was not observed in
2fTGH cells transfected with the empty vector (Fig. 2B, lane
1) nor in a blot incubated with preimmune serum (Fig. 2B
Bottom).
The recognition of endogenous CIITA by the a-CIITA
antibody in two B cell extracts was a final test of this antibody.
A 145-kDa band, which migrated at the same position as
recombinant CIITA, was detected by the a-CIITA antibody in
a Western blot (Fig. 2C, lanes 1–3). The same band was not
observed with a-FLAG antibody or preimmune serum.
A ProlineySerineyThreonine-Rich Region Is Essential for
the Transactivation Activity of CIITA. The N terminus of
CIITA contains an acidic domain (amino acids 30–160),
followed by domains rich in proline (amino acids 163–195),
serine (amino acids 209–237), and threonine (amino acids
260–322) (11). Acidic domain has been found in many tran-
scription factors (30–34), and others (35, 36) have shown that
the acidic domain of CIITA can function as an activation
domain when fused to the GAL-4 DNA-binding domain. One
of these reports (36) also replaced the acidic and proline-,
serine-, and threonine-rich domains in the fusion construct
with the acidic domain of HSV1 transcription activation factor
(aTIF) and showed reduced function. This result suggests that
either the acidic domain alone is not sufficient to activate the
MHC class II promoter, or the heterologous HSV1 a-TIF
acidic domain behaved differently from the CIITA acidic
domain. Proline-, serine-, and threonine-rich domains have
been found in many transcriptional factor and have a proposed
role in protein–protein interaction (30, 37). Therefore, it was
important to determine the contribution of each domain to the
activity of native CIITA.
Mutant CIITA(D132–301) (Fig. 3A), which retains the acidic
domain but deletes the proline-, serine-, and threonine-rich
domains, was analyzed. This mutant did not exhibit any
activation activity when transfected with pDRA300CAT (Fig.
3A, compare lanes 2 and 3). This indicates that the acidic
domain alone is not sufficient to activate the MHC class II
promoter, and intact proline-, serine-, and threonine-rich
regions are also necessary. To better define the function of
proline-, serine-, and threonine-rich domains of CIITA, two
mutants, CIITA(D132–209) and CIITA(D209–301), were
made. CIITA(D132–209) has a clean deletion of the proline-
rich domains (amino acids 132–209), and this deletion did not
affect the activation of DRA promoter by CIITA (Fig. 3A, lane
4). Deletion of the serine- threonine-rich domains in mutant
CIITA(D209–301) also did not affect transactivation function
(Fig. 3A, lane 5). One possible explanation is that the two
subdomains may serve overlapping functions, although the
analysis performed cannot rule out unexpected compensatory
changes in protein fold in any of these mutants.
To ascertain that the low activity of these mutants was not
due to low expression of mutant proteins, cell extracts were
made and blotted with the a-CIITA antibody. The mutants
produced comparable levels of protein as the wild-type con-
struct (Fig. 3B). These results can also be confirmed with the
antibody against the FLAG epitope (data not shown).
CIITA Function Requires a GTP-Binding Motif. Analysis of
the primary amino acids of CIITA shows that a region of
CIITA from residues 421 to 561 has a significant homology to
a wide variety of GTP-binding proteins in the Ras superfamily,
including the low-molecular weight Ras-like GTPase, the
translation elongation factor (EF-TU), and the a subunits of
heterotrimeric G protein (38). CIITA exhibits similarities to
three consensus motifs found in other GTP-binding domains:
the phosphate-binding motif GXXXXGKS, the Mg21-binding
motif DXXG, and the guanine-binding motif SKXD (Fig. 4).
These sequence motifs are also referred to as G-1, G-3, and
G-4, respectively. The G-1 region of CIITA (GX4GKS) has a
perfect match to the conserved amino acid sequence of p21ras
(10GX4GKS17). The «-amino group of Lys16 (corresponding to
Lys427 of CIITA) forms bonds with the a- and b-phosphate of
GTP or GDP (39, 40). The G-3 region, 461DX2G464, of CIITA
is also conserved and it corresponds to residues 57–60,
FIG. 2. Detection of recombinant and endogenous CIITA. (A) Detection of transfected FLAG.CIITA8 by immunoblot. 2fTGH and COS-7 cells
were transfected with 10 mg and 2 mg, respectively, of either FLAG.CIITA8 (lanes 2 and 4) or empty vector pcDNA3 (lanes 1 and 3). The cells
were harvested 24 h after the transfection, and total lysates were prepared and separated on a 8% SDSypolyacrylamide gel. The gel was transferred
onto nitrocellulose and the presence of recombinant CIITA was examined with 10 mgyml a-FLAG antibody. (B) Transfected FLAG.CIITA8 was
detected by both a-FLAG and a-CIITA antibodies. 2fTGH and RJ2.2.5 cells were transfected with either 10 mg (lanes 2 and 4) or 5 mg (lane 3)
of FLAG.CIITA8 or control vector pcDNA3 (lane 1). Total lysates were prepared and examined with either a-FLAG antibody (Top), a-CIITA
antibody (Middle), or preimmune serum (Bottom). (C) Anti-CIITA antibody specifically recognizes an endogenous CIITA, with an apparent
molecular weight of 145 kDa. Two Namalwa and one Raji nuclear extracts were prepared and blotted with either the a-FLAG antibody (Top),
a-CIITA antibody (Middle), or preimmune serum (Bottom).
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57DX2G60, of p21ras. In p21ras, the invariant aspartate (position
461 in CIITA) binds the catalytic Mg21 through an intervening
water molecule, while the amide proton of the invariant glycine
(position 464 of CIITA) forms a hydrogen bond with g-phos-
phate of GTP. The G-4 region of CIITA, 558SKXD561, is
identical to the p21ras G-4 region (residues 116–119,
116NKXD119) except position 558 of CIITA has a serine residue
instead of an asparagine or threonine residue and this change
does not affect CIITA’s function (see below). Collectively,
these homologies suggest that CIITA may exhibit guanine
nucleotide-binding activity. To determine if these motifs are
significant, each motif was individually mutated (Fig. 5A) and
examined for transactivation activity. The mutants were co-
transfected with the pDRA300CAT into G3A cells, and CAT
activity was determined. CIITA-GTP1(DGK), which con-
tained a deletion of residues 421–422 in the phosphate-binding
motif, showed a reduced transactivation activity (22% above
the basal activity and 38% of the wild-type controls; Fig. 5A,
lanes 1–3). CIITA-GTP1(K 3 E) contains a substitution of
Lys427 (K) to Glu (E) and also exhibits greatly reduced activity
(lane 4). The transactivation capability of CIITA-
GTP2(DDAYG) and CIITA-GTP3(DSKAD) constructs is
also greatly diminished (Fig. 5A, lanes 5 and 6).
A Western blot was performed to ensure that all constructs
expressed CIITA to a comparable level as the that of wild-type
protein (Fig. 5B). The only exception is CIITA-
GTP2(DDAYG) (lane 3), which showed a lower level of
protein expression. This is consistent with reports which
showed that this region is crucial for protein stability (41–43).
These results, in total, strongly suggest that CIITA contains
putative GTP-binding motifs.
Transdominant-Negative Mutants of CIITA. CIITA repre-
sents a highly specific, yet potent, regulator of MHC class II
genes. Any interference with its function is likely to signifi-
cantly affect antigen presentation by MHC class II-mediated
pathway and subsequent T cell activation, and such interfer-
ence may be desirable in a number of diseases. The capacity of
all CIITAmutants to serve as transdominant-negative mutants
of CIITA function was tested in G3A. Two mutants exhibit
transdominant-negative properties as shown in Table 1. The
experiment consisted of the cotransfection of the pDRA-
CAT300 reporter together with CIITA and an empty vector
(pcDNA3), or a mutant form of CIITA. A titration of wild-
type vs. mutant CIITA constructs established that a 1:1 ratio
was sufficient to reveal transdominant-negative function (data
not shown). Two mutants, CIITA(D132–301) and CIITA-
GTP2(DDAYG) greatly reduced the function of wild-type
CIITA, with maximal reduction of wild-type CIITA function
by '96%. We also tested these two transdominant-negative
mutants in another CIITA-deficient cell, RJ2.2.5 (13), and
these two mutants also efficiently blocked the function of
wild-type CIITA, as shown in Table 2. The effects of these
transdominant mutants is gene-specific, since the TAP1 pro-
moter (44) is not affected by them (data not shown).
DISCUSSION
CIITA is a master regulator for all known genes involved in the
class II antigen presenting pathway, including MHC class II
(11, 19, 21), invariant chain (19, 22), and DM genes (22).
CIITA transcript is expressed constitutively in B cells, and it is
induced in cells such as fibroblasts, macrophages, and glio-
blastoma cells upon treatment with IFN-g (19–21). The kinetic
of CIITA induction by IFN-g precedes the induction of MHC
class II transcripts, and introduction of CIITA alone into a
number of cell types is sufficient to activate class II genes.
However, the mode of action of CIITA is not well understood.
In this analysis, an extensive mutation analysis was undertaken,
and the consequences on DRA promoter activation were
assessed by introducing these mutants into a CIITA-negative,
IFN-g-defective mutant cell, G3A (19). The results show that
the acidic domain alone is insufficient to activate the DRA
promoter and requires an additional prolineyserine-rich or
threonine-rich domain to achieve activity. Most intriguing,
guanine-nucleotide binding motifs within residues 420–561 are
found to be essential for CIITA activity. Preliminary data have
confirmed that CIITA can bind GTP (K.-C.C., J. Harton, and
FIG. 4. Analysis of guanine nucleotide-binding motifs within
CIITA. The amino acid residues of CIITA from 421 to 561 were
aligned with the consensus sequence of GTPase and Ras. The bold
letters are sequences within CIITA that are found in the GTPase
consensus motifs. The number in the parentheses indicates the spacing
between the motifs.
FIG. 3. Requirement for proline-rich or serineythreonine-rich domain in addition to the acidic domain for CIITA activity. (A) G3A cells were
cotransfected with the pDRA300CAT and pcDNA3 (lane 1), FLAG.CIITA8 (lane 2), or mutant constructs (lanes 3–5). The cells were harvested
48 h after transfection. CAT activity was analyzed and quantitated by PhosphorImager (Molecular Dynamics). The relative level of expression was
calculated by using the wild-type control as a value of 1. These experiments were repeated three times. (B) Immunoblot analysis of wild-type
FLAG.CIITA8 and mutant constructs. Cells transfected with FLAG.CIITA and mutant CIITA were harvested and lysed 24 h after transfection.
Equivalent amount of total lysates from each sample was fractionated on 8% SDS-PAGE. The blot was examined with the a-CIITA antibody and
visualized by ECL, according to the manufacturer’s specification. All of the mutant constructs were expressed at a comparable level to the
FLAG.CIITA8. No band was observed in cells transfected with the empty vector pcDNA3 (lane 1).
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J.P.-Y.T., unpublished work) placing CIITA in a novel group
of transcription factors. Two of these mutants are potent
transdominant repressors of CIITA function. It may be pos-
sible to utilize these transdominant mutants to downregulate
MHC class II expression and function in vivo.
Functional Role of Acidic and ProlineySerineyThreonine-
Rich Domains of CIITA.Acidic and prolineyserineythreonine-
rich domains are found in many activators or coactivators
involved in gene expression (30, 37, 45, 46). Activation domains
can be grouped into several categories by their amino acids
content, including glutamine, acidic, proline, serine, and threo-
nine domains. These domains have been shown to interact with
the basal transcriptional machinery by in vitro and in vivo assays
(30, 47). The interaction of the activation domain and basal
transcription factors is believed to be responsible for gene
activation by increasing the rate by which other basal tran-
scription factors and RNA polymerase II bind to the TATA
box and the initiator (48–52). The proline domain is found in
CTFyNF1 and AP-2, among others, and it interacts with the
TATA box-binding protein (TBP; ref. 30) and the TFIIB. For
CIITA, two groups (35, 36) showed that the acidic domain can
function as an activation domain when fused to a GAL-4
DNA-binding domain. The findings here, using native CIITA
protein, reveal a role for both the acidic and the proliney
serineythreonine-rich domain. This parallels findings with
other transcription factors that contain an acidic domain (45,
53). In these factors, the acidic domain does not function by
itself, but in conjunction with the proline- or serineythreonine-
rich domains. One unique feature of CIITA that has to be
considered in any working model is that CIITA does not
appear to contact DNA. Thus, it is likely that CIITA uses the
functional domains defined here to interact with basal tran-
scription factor or other DNA-binding protein.
A Guanine Nucleotide-Binding Motif Is Unique to CIITA.
Guanine nucleotide-binding motifs play important roles in a
large number of basic cellular functions including protein
synthesis, signal transduction, and intracellular protein trans-
port, but they have not been associated with transcription
factors (54, 55). A comparison of the primary amino acids of
CIITA to known guanine nucleotide-binding proteins reveals
a region that is highly identical to the GTP-binding domain of
RAS (Fig. 4), except a serine replaces the asparagine or
threonine residue in CIITA. Point mutation of the serine to
asparagine did not affect the activity of CIITA, indicating a
flexibility of this residue. Mutation of any of the other three
conserved motifs either reduces or abolishes the CIITA ac-
tivity. In particular, CIITA-GTP1(K 3 E), which contains a
single point mutation at the phosphate-binding motif, shows a
drastically reduced transacting activity. In the Ras protein, this
residue is shown by x-ray crystallography to interact with the
a- and b-phosphate of GTP or GDP and is crucial for function.
Our finding is in accordance with the findings in Ras (56).
GTP-binding proteins exist in two different states: an active
GTP-bound form and an inactive GDP-bound form (57). The
transition from the active GTP-bound to the inactive GTP-
bound form is usually accompanied by a conformational
change in the protein, and this change affects the recruitment
or the interaction with downstream factors. GTP binding may
similarly modify the function of CIITA. GTP-binding proteins
are also involved in protein transport (58). Therefore, it is
possible that a GTP bound CIITA may transport a positive
factor(s) from the cytoplasm to nucleus or a negative nuclear
regulator out of the nucleus. Our recent data showed that the
FIG. 5. Guanine nucleotide-binding motifs are essential for CIITA activity. (A) G3A cells were cotransfected with the pDRA300CAT and
pcDNA3 (lane 1), FLAG.CIITA8 (lane 2), or mutant CIITA (lanes 3 to 6). Cells were harvested 48 h later, and CAT activity was determined as
described. The experiment was repeated three times. (B) Western blot to assess the level of protein expression by mutant CIITA genes (compare
lane 1 and lanes 2–4; also compare lanes 5 and 6). An equal amount of total lysates was loaded, separated by SDSyPAGE, and transferred onto
nitrocellulose. The blot was probed with the a-CIITA antibody. ns, Nonspecific band.
Table 1. Transdominant repression of DRACAT expression by
CIITA mutants in G3A
Parameters 1 2 3
pDRA300CAT 1 1 1





% inhibition* — 96.3 91.2
*Wild-type FLAG.CIITA8 was cotransfected with pDRA300CAT in
the presence of control, pcDNA3, or different mutant forms of
CIITA. The subsequent CIITA activity of each sample was assessed
and the transdominant-negative function of the mutant constructs
was calculated as (average of four experiments):
% inhibition2 100% 2
CAT activity of column 2 or 3
CAT activity of column 1
3 100%.
Table 2. Transdominant repression of DRACAT expression by
CIITA mutants in RJ2.2.5
Parameters 1 2 3
pDRA300CAT 1 1 1





% inhibition* — 94.5 97.2
*Wild-type FLAG.CIITA8 was cotransfected with pDRA300CAT in
the presence of control, pcDNA3, or different mutant forms of
CIITA. The subsequent CIITA activity of each sample was assessed
and the transdominant-negative function of the mutant constructs
was calculated as (average of three experiments):
% inhibition2 100% 2
CAT activity of column 2 or 3
CAT activity of column 1
3 100%.
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wild-type CIITA can bind GTP, and mutation of any of the
three GTP-binding motifs abrogated the CIITA’s GTP-
binding activity (K.-C.C., J. Harton, and J.P.-Y.T., unpublished
work).
Identification of CIITA Transdominant-Negative Mutants.
The identification of transdominant-negative mutants of CI-
ITA has both practical and molecular implications. From a
practical point of view, these mutants may be efficient in
suppressing MHC class II promoter function and gene expres-
sion in an in vivo condition. For example, it may be possible to
produce animals bearing such transdominant-negative CIITA
molecules and use these for transplant purposes. From a
scientific point of view, it is of interest that deletionymutation
of two specific domains resulted in potent and highly efficient
transdominant-negative functions. Presumably, what remained
nonmutated in these molecules is sufficient to block the
function of wild-type CIITA, perhaps by interceding certain
intracellular signals. The fact that the transdominant-negative
function is observed at a 1:1 ratio of wild-type:mutant CIITA
suggests that the mutant form is more efficient at interceding
such a putative signal or function.
In summary, this report shows several functional domains
important for the function of CIITA, including highly unusual
domains that have not been previously associated with tran-
scription factors. Mutations of CIITA result in potent trans-
dominant molecules, which may be of practical and therapeutic
use.
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